Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH139210D
- Pages: 53
- October 2018
- Total Views:1117
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company's pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is intended to treat rritable bowel syndrome with constipation. Synthetic Biologics' SYN-004 is an oral prophylactic therapy for prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop its product candidates. Synthetic Biologics is headquartered in Rockville, Maryland, the US.
Synthetic Biologics Inc (SYN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13
Venture Financing 15
SeeChange Health Raises USD 3 Million In Venture Financing 15
Partnerships 16
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16
Intrexon Enters into Partnership with Synthetic Biologics 17
Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19
Licensing Agreements 20
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20
Equity Offering 22
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28
Synthetic Biologics Completes Public Offering Of Shares For USD 13.2 Million 30
Synthetic Biologics Completes Private Placement Of Common Stock For USD 11 Million 31
Acquisition 32
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32
Synthetic Biologics Inc-Key Competitors 33
Synthetic Biologics Inc-Key Employees 34
Synthetic Biologics Inc-Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Aug 08, 2018: Synthetic Biologics reports second quarter 2018 operational highlights and financial results 36
May 08, 2018: Synthetic Biologics Reports First Quarter 2018 Operational Highlights And Financial Results 37
Feb 22, 2018: Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results 39
Nov 01, 2017: Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results 40
Aug 03, 2017: Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results 41
May 04, 2017: Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results 43
Mar 02, 2017: Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results 45
Corporate Communications 47
May 22, 2018: Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American 47
Mar 07, 2018: Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan 48
Dec 05, 2017: Synthetic Biologics Announces Management Changes 49
Product News 50
01/18/2017: Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA 50
Clinical Trials 51
Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List Of Figure
List of Figures
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13
SeeChange Health Raises USD 3 Million In Venture Financing 15
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16
Intrexon Enters into Partnership with Synthetic Biologics 17
Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28
Synthetic Biologics Completes Public Offering Of Shares For USD 13.2 Million 30
Synthetic Biologics Completes Private Placement Of Common Stock For USD 11 Million 31
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32
Synthetic Biologics Inc, Key Competitors 33
Synthetic Biologics Inc, Key Employees 34
Synthetic Biologics Inc, Subsidiaries 35
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Synthetic Biologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company's pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is intended to treat rritable bowel syndrome with constipation. Synthetic Biologics' SYN-004 is an oral prophylactic therapy for prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop its product candidates. Synthetic Biologics is headquartered in Rockville, Maryland, the US.
Synthetic Biologics Inc (SYN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13
Venture Financing 15
SeeChange Health Raises USD 3 Million In Venture Financing 15
Partnerships 16
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16
Intrexon Enters into Partnership with Synthetic Biologics 17
Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19
Licensing Agreements 20
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20
Equity Offering 22
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28
Synthetic Biologics Completes Public Offering Of Shares For USD 13.2 Million 30
Synthetic Biologics Completes Private Placement Of Common Stock For USD 11 Million 31
Acquisition 32
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32
Synthetic Biologics Inc-Key Competitors 33
Synthetic Biologics Inc-Key Employees 34
Synthetic Biologics Inc-Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Aug 08, 2018: Synthetic Biologics reports second quarter 2018 operational highlights and financial results 36
May 08, 2018: Synthetic Biologics Reports First Quarter 2018 Operational Highlights And Financial Results 37
Feb 22, 2018: Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results 39
Nov 01, 2017: Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results 40
Aug 03, 2017: Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results 41
May 04, 2017: Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results 43
Mar 02, 2017: Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results 45
Corporate Communications 47
May 22, 2018: Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American 47
Mar 07, 2018: Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan 48
Dec 05, 2017: Synthetic Biologics Announces Management Changes 49
Product News 50
01/18/2017: Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA 50
Clinical Trials 51
Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List Of Figure
List of Figures
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List Of Table
List of Tables
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Synthetic Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR 13
SeeChange Health Raises USD 3 Million In Venture Financing 15
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention 16
Intrexon Enters into Partnership with Synthetic Biologics 17
Synthetic Biologics and Enterome Bioscience Enter into Research Agreement 18
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases 19
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center 20
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares 22
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares 23
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants 24
Synthetic Biologics Raises USD46 Million in Public Offering of Shares 26
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units 28
Synthetic Biologics Completes Public Offering Of Shares For USD 13.2 Million 30
Synthetic Biologics Completes Private Placement Of Common Stock For USD 11 Million 31
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics 32
Synthetic Biologics Inc, Key Competitors 33
Synthetic Biologics Inc, Key Employees 34
Synthetic Biologics Inc, Subsidiaries 35
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Synthetic Biologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020